Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
Operating Income Scaling
Trending higher, above historical average, structural decline.
Left:
||||
Profit from core business operations before interest and taxes
Latest
$-21.48M
↑ 45% above average
Average (9y)
$-38.87M
Historical baseline
Range
High:$-21.48M
Low:$-65.81M
CAGR
-11.7%
Structural decline
| Period | Value | Change |
|---|---|---|
| 2024 | $-21.48M | +13.2% |
| 2023 | $-24.73M | -9.8% |
| 2022 | $-22.52M | +54.2% |
| 2021 | $-49.21M | -86.1% |
| 2020 | $-26.45M | +32.0% |
| 2019 | $-38.88M | +7.0% |
| 2018 | $-41.80M | -7.4% |
| 2017 | $-38.90M | +34.0% |
| 2016 | $-58.97M | +10.4% |
| 2015 | $-65.81M | - |